Trial Profile
A multicenter, open-label, randomized, study to compare the efficacy and safety of indinavir 800 mg b.i.d. [twice daily] plus ritonavir 100 mg b.i.d. plus two NRTIs [nucleoside reverse transcriptase inhibitor] vs. nelfinavir 1250 mg b.i.d. plus two NRTIs in HIV-1 seropositive patients who have failed or are intolerant to an NNRTI [non-nucleoside reverse transcriptase inhibitor] containing regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Indinavir (Primary) ; Nelfinavir; Nucleoside reverse transcriptase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 18 Oct 2007 New trial record.